Afya Limited (NASDAQ:AFYA) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Eight analysts give Afya a consensus “Hold” rating (1 sell, 6 hold, 1 buy) and the average 1‑year price target is $17.30.
• Recent analyst actions are mixed — JPMorgan and UBS trimmed price targets while Zacks downgraded to a “strong sell” and Wall Street Zen cut to “buy” — highlighting diverging views on the stock.
• Institutional ownership is high at 88.02%, with recent new or increased stakes from XTX Topco, Mangrove Partners, State Street, Campbell & CO and Banco BTG Pactual, signaling continued institutional interest.

Afya Limited (NASDAQ:AFYA - Get Free Report) has been given an average recommendation of "Hold" by the eight research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $17.30.

Several research firms have recently commented on AFYA. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $22.00 target price (down from $24.50) on shares of Afya in a research note on Wednesday, January 7th. Wall Street Zen cut Afya from a "strong-buy" rating to a "buy" rating in a report on Saturday, January 31st. Zacks Research lowered Afya from a "hold" rating to a "strong sell" rating in a research report on Friday, January 9th. UBS Group reissued a "neutral" rating and set a $16.00 price objective (down from $18.00) on shares of Afya in a report on Friday, January 16th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Afya in a research report on Wednesday, January 21st.

Hedge Funds Weigh In On Afya

Several large investors have recently bought and sold shares of AFYA. XTX Topco Ltd bought a new position in Afya in the fourth quarter valued at approximately $215,000. Mangrove Partners IM LLC bought a new stake in shares of Afya during the 4th quarter valued at $197,000. State Street Corp lifted its stake in shares of Afya by 25.8% in the 4th quarter. State Street Corp now owns 126,914 shares of the company's stock valued at $1,955,000 after purchasing an additional 26,005 shares during the period. Campbell & CO Investment Adviser LLC lifted its stake in shares of Afya by 45.3% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 39,683 shares of the company's stock valued at $612,000 after purchasing an additional 12,365 shares during the period. Finally, Banco BTG Pactual S.A. bought a new position in shares of Afya in the 4th quarter worth $462,000. 88.02% of the stock is currently owned by institutional investors and hedge funds.

Afya Stock Performance

Shares of Afya stock opened at $13.86 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.98 and a quick ratio of 0.98. The firm has a 50 day simple moving average of $14.53 and a 200 day simple moving average of $14.81. Afya has a fifty-two week low of $13.00 and a fifty-two week high of $19.90. The firm has a market cap of $1.30 billion, a P/E ratio of 9.97, a P/E/G ratio of 0.67 and a beta of 0.52.

Afya Company Profile

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya's offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.